Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

68.17EUR
15 Feb 2019
Change (% chg)

€2.62 (+4.00%)
Prev Close
€65.55
Open
€65.18
Day's High
€68.50
Day's Low
€65.09
Volume
4,044,916
Avg. Vol
3,537,819
52-wk High
€103.74
52-wk Low
€58.34

Chart for

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 22.18 30.48 33.70
EPS (TTM): 5.29 -- --
ROI: 8.69 14.95 14.45
ROE: 16.39 16.27 15.96

Bundesliga Top Scorers

Feb 15 (OPTA) - Top Scorers in the Bundesliga on Friday 1 L. Jović (Eintracht Frankfurt) 14 2 R. Lewandowski (Bayern München) 13 M. Reus (Borussia Dortmund) 3 Paco Alcácer (Borussia Dortmund) 12 4 S. Haller (Eintracht Frankfurt) 11 T. Werner (Leipzig) 5 O. Duda (Hertha Berlin) 10 A. Finnbogason (Augsburg) A. Pléa (Borussia Mönchengladbach) Y. Poulsen (Leipzig) 6 T. Hazard (Borussia

15 Feb 2019

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

15 Feb 2019

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

15 Feb 2019

UPDATE 1-Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

* Bayer gains full control over drug Vitrakvi (larotrectinib)

15 Feb 2019

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT, Feb 15 German drugmaker Bayer acquired all rights it does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly's Loxo Oncology.

15 Feb 2019

Bayer stresses drug's tolerability in bid for prostate cancer market

FRANKFURT Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.

14 Feb 2019

Bayer stresses drug's tolerability in bid for prostate cancer market

FRANKFURT, Feb 14 Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.

14 Feb 2019

German stocks - Factors to watch on Feb. 12

BERLIN, Feb 12 The following are some of the factors that may move German stocks on Tuesday:

12 Feb 2019

Exclusive: Bayer's Monsanto wins arbitration ruling over royalties from Indian seed company

NEW DELHI German drugmaker Bayer AG's Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd (NSL) in a royalty dispute, lawyers familiar with the matter said.

11 Feb 2019

Exclusive: Bayer's Monsanto wins arbitration ruling over royalties from Indian seed company

NEW DELHI German drugmaker Bayer AG's Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd (NSL) in a royalty dispute, lawyers familiar with the matter said.

11 Feb 2019

Earnings vs. Estimates